OTR-AC, also known as OT-R antagonist or Oxytocin Antagonist, is a selective oxytocin receptor antagonist developed by Ferring Pharmaceuticals. It is currently in early-stage clinical development as a potential therapeutic agent for various medical conditions, including preterm labor and endometriosis. In this article, we will provide an overview of the OTR-AC chemical name, molecular formula, formula weight, and CAS no. We will also discuss the top searched keywords on Google, health benefits, potential effects, mechanisms, safety, dosage information, and side-effects associated with OTR-AC.
Chemical Name, Molecular Formula, Formula Weight, and CAS No:
OTR-AC is a selective oxytocin receptor antagonist.
OTR-AC has shown promise as a potential treatment for various medical conditions, including preterm labor and endometriosis. It has demonstrated efficacy in preventing preterm labor and premature delivery in preclinical studies. Furthermore, OTR-AC has shown potential as a therapy for endometriosis by inhibiting the growth of endometrial tissue.
Potential Effects and Mechanisms:
OTR-AC selectively blocks the oxytocin receptor, which plays an essential role in promoting uterine contractions during labor. Its mechanism of action involves inhibiting the oxytocin-induced increase in calcium ions within uterine smooth muscle cells, leading to decreased uterine contractions. OTR-AC may also exert anti-inflammatory effects by inhibiting the release of pro-inflammatory cytokines, such as interleukins and tumor necrosis factor alpha.
OTR-AC appears to have a favorable safety profile in early-stage clinical studies. However, more extensive clinical trials are necessary to evaluate the safety and efficacy of OTR-AC fully.
While OTR-AC appears to have a favorable safety profile, there are potential side-effects associated with its use, including headache, nausea, and vomiting. Therefore, it is essential to talk to a healthcare provider before taking OTR-AC to determine if it's the right treatment for you.
OTR-AC is still in the early stages of clinical development, and there is no approved dosage information available. Dosage and administration are currently being evaluated in clinical trials.
OTR-AC shows promising potential as a therapeutic agent for various medical conditions, such as preterm labor and endometriosis. Its ability to selectively block the oxytocin receptor offers a potentially safer and more effective alternative to traditional tocolytic agents associated with adverse effects such as maternal hypotension and pulmonary edema. More extensive clinical trials are still necessary to evaluate the safety and efficacy of OTR-AC fully. Therefore, it is crucial to talk to a healthcare provider before taking any medication, including OTR-AC.